Investigational drug · Phase 3
BMS-986348
Also called: CC-92480, mezigdomide
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
17
Any phase or sponsor naming "BMS-986348"
First trial start
2015
Oct 2015
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986348", any sponsor or status.
- Phase 113
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986348" as an intervention, largest first.
- A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
CelgeneBristol Myers Squibb (BMY)
NCT05519085 · 810 participants (planned) · Start Sep 20, 2022 · Primary completion Jan 10, 2027
Drug: mezigdomide; Pomalidomide and 2 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Los Alamitos, California; San Diego, California; West Hollywood, California · 266 sites in all
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05552976 · 606 participants · Start Jan 10, 2023 · Primary completion Sep 28, 2026
Drug: Mezigdomide; Carfilzomib and 1 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Mobile, Alabama; Cerritos, California; Irvine, California · 204 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT03989414 · 424 participants (planned) · Start Sep 30, 2019 · Primary completion Nov 30, 2026
Drug: CC-92480; Bortezomib and 6 more · For: Multiple Myeloma
Sites: Denver, Colorado; Tampa, Florida; Atlanta, Georgia · 49 sites in all
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsPivotal-lookingRecruiting
Karyopharm Therapeutics IncIndustry
NCT02343042 · 300 participants (planned) · Start Oct 2015 · Primary completion Apr 2027
Drug: Selinexor; Dexamethasone and 10 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Los Angeles, California; Denver, Colorado · 25 sites in all
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05372354 · 260 participants (planned) · Start Oct 18, 2022 · Primary completion Oct 12, 2026
Drug: CC-92480; Tazemetostat and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Baltimore, Maryland; Boston, Massachusetts · 17 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT03374085 · 200 participants · Start Feb 6, 2018 · Primary completion Aug 20, 2025
Drug: CC-92480; Dexamethasone · For: Multiple Myeloma
Sites: Duarte, California; Atlanta, Georgia; Boston, Massachusetts · 54 sites in all
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06121843 · 187 participants (planned) · Start Feb 22, 2024 · Primary completion Aug 1, 2028
Drug: BMS-986393; Alnuctamab and 4 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 19 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT06988488 · 62 participants (planned) · Start Oct 7, 2025 · Primary completion May 31, 2027
Drug: Elranatamab; Mezigdomide and 1 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; New Haven, Connecticut; Hackensack, New Jersey · 22 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05707390 · 32 participants · Start Feb 20, 2023 · Primary completion Sep 13, 2023
Drug: Mezigdomide · For: Hepatic Impairment
Sites: Miami Lakes, Florida; Orlando, Florida; San Antonio, Texas
Roswell Park Cancer InstituteAcademic, hospital or other
NCT06627751 · 28 participants (planned) · Start May 1, 2025 · Primary completion May 1, 2027
Drug: Mezigdomide; Carfilzomib and 1 more · For: Extramedullary Disease in Multiple Myeloma; Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Sites: Buffalo, New York
Newest research
PubMed records naming it or its code names, newest first.
- Phase 3 trial data point to more options for patients with relapsed or refractory multiple myeloma: Teclistamab- and mezigdomide-based regimens could expand treatment options, set new standards of care, and improve survival.
Lawrence L · Cancer 2026
- Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid-derived suppressor cells by myeloma cells.
Niiyama-Uchibori Y, Tsukamoto T, Inoue Y, et al. · Br J Haematol 2026
- Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.
Bazarbachi AH, Lentzsch S, Facon T, et al. · J Clin Oncol 2026
- Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.
Niklas H, Bold A, Völkl S, et al. · Ann Hematol 2026
- Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma.
Cani L, Mina R, Lonial S · Cancer J 2026
- Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.
Chiu H, Zhao J, Basavanhally T, et al. · Blood 2026
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.